Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 29, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of shareholding changes within an employee retirement plan and does not contain financial performance data.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan") due to fund movements:
- August 24, 2006: Holdings decreased from 17,413,603 to 17,370,806 ADRs at an average price of $54.87.
- August 25, 2006: Holdings increased from 17,370,806 to 17,434,558 ADRs at an average price of $54.88.
These transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the mechanics of the retirement plan's share adjustments.
Important Facts for Investors to Verify
- The Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
- Directors Dr. J. P. Garnier and Dr. M. M. Slaoui are potentially interested in the shares held in the fund in the same manner as other employees.
- The reported share movements reflect fund activity rather than direct trading by the directors themselves.